KR930012015A - 질 감염의 치료에 유용한 리팍시민을 함유하는 의약조성물 - Google Patents

질 감염의 치료에 유용한 리팍시민을 함유하는 의약조성물 Download PDF

Info

Publication number
KR930012015A
KR930012015A KR1019920012471A KR920012471A KR930012015A KR 930012015 A KR930012015 A KR 930012015A KR 1019920012471 A KR1019920012471 A KR 1019920012471A KR 920012471 A KR920012471 A KR 920012471A KR 930012015 A KR930012015 A KR 930012015A
Authority
KR
South Korea
Prior art keywords
vaginal
composition
rifaximin
valve
treatment
Prior art date
Application number
KR1019920012471A
Other languages
English (en)
Other versions
KR0149519B1 (ko
Inventor
마치 에지디오
가브리엘 로티니 레온
데사이 슈바쉬.
그릴리 마시모
Original Assignee
귀도 게라
알파 와셔만 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 귀도 게라, 알파 와셔만 에스.피.에이 filed Critical 귀도 게라
Publication of KR930012015A publication Critical patent/KR930012015A/ko
Application granted granted Critical
Publication of KR0149519B1 publication Critical patent/KR0149519B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 질 감염, 특히 세균성 질 질환의 치료에 유용한 치료적 유효량의 리팍시민을 함유하는, 국소 경로를 통해 투여가능한 특히 질 포옴 및 연고형태의 질 의약 조성물에 관한 것이다.

Description

질 감염의 치료에 유용한 리팍시민을 함유하는 의약조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 치료에 유효한 양의 리팍시민과 함께 질에 사용가능한 캐리어를 함유하는 질 의약 조성물.
  2. 제1항에 있어서, 50-500㎎의 리팍시민을 함유하는 조성물.
  3. 제1항에 있어서, 질 포옴 형태인 조성물.
  4. 제1항에 있어서, 연고 형태인 조성물.
  5. 제1항에 있어서, 크림,젤, 질 오불, 질 캡슐, 질 절에 또는 질 비등 정제의 형태인 조성물.
  6. 제3항에 있어서, 100미크론 이하의 입자크기를 가지는 미립자화 피팍시민2-8 중량%, 중점제 2-6 중량%, 유성물질 86-96 중량%를 함유하는 현탁액으로 구성되는 조성물로서, 이 조성물은 알루미늄 카스니터 내에 충진 되며 이 카니스터는 에폭시페놀 수지로 된 코팅에 의해 내부가 보호되고 폴리에틸렌 밸브로 밀폐되며 밸브를 통해 현탁액의 60-100 중량% 양의 프로펠란트 기체가 주입되는 것을 특징으로 하는 조성물.
  7. 제6항에 있어서, 유성물질은 광유 USP, 액체 파라핀, 바셀린오일, 카프릴산과 카프린산의 트리글리세라이드 및 폴리옥시에틸렌화 올레인산 글리세라이드 중에서 선택되는 조성물.
  8. 제6항에 있어서, 증점제는 세틸 스테아릴 알콜, 경화 카스토르유 및 밀랍중에서 선택되는 조성물.
  9. 제6항에 있어서,프로펠란트 기체는 순수물 또는 혼합물로서의 기체 탄화수소, 클로로플루오로카본, 플루오로카본, 이산화탄소, 질소, 불활성기체 및 이러한 물질의 혼합물 중에서 선택되는 조성물.
  10. 제9항에 있어서, 프로펠란트 기체는 디클로로디플루오로메탄, 프로판, n-부탄, 이소부탄 및 이러한 물질의 혼합물 중에서 선택되는 조성물.
  11. 다음과 같은 단계로 이루어지는 것을 특징으로 하는 리팍시민을 함유하는 질 포옴 형태의 조성물의 제조방법.
  12. a)50°-80°C의 온도의 멜터내에서 분량의 유성물질중에 중점제를 융해시켜 용액을 제조하는 단계, b) 균등기 내에서 약한 진공하에 30분간 느린속도의 교반하에 100 미크론 이하의 입자크기를 가지는 미립자화 리팍시민을 나머지 분량의 유성물질 중에 현탁시키는 단계, c) 40°-50°C로 냉각시킨 a)단계의 용액을 약한 진공하에 느린 속도의 교반하에 b)단계의 현탁액에 가하면서 실온으로 냉각시키는 단계, d)c)단계에서 얻어진 현탁액을 카니스터네에 충진시키는 단계, e) 카니스터를 폴리에티렌 밸브로 밀폐시키고 이 밸브를 통해 프로펠란트 기체를 주입 시키는 단계, f) 카니스터의 밸브에 폴리에틸렌 액튜에이터 및 어플리케이터를 부착시키는 단계.
  13. 활성성분으로서 리팍시민을 함유하는 질 감염 치료용 의약.
  14. 제12항에 있어서, 질 감염은 세균성 질 질환을 포함하는 것을 특징으로 하는 의약.
  15. 질 감염의 치료가 필요한 환자에 대해 치료에 유효한 양의 리팍시민을 국소경로에 의해 투여시키는 것을 특징으로 하는 질 감염의 치료방법.
  16. 제14항에 있어서, 질 감염은 세균성 질 질환을 포함하는 것을 특징으로 하는 치료방법.
  17. 제14항에 있어서, 상기 국소투여는 질 포옴에 의해 수행되는 것을 특징으로 하는 치료방법.
  18. 제14항에 있어서, 상기 국소투여는 연고에 의해 수행되는 것을 특징으로 하는 치료방법.
  19. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920012471A 1991-12-17 1992-07-14 질감염 치료용 질의약 조성물과 그 제조 방법 KR0149519B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITBO91A000476 1991-12-17
IT8091A000476 1991-12-17
ITBO910476A IT1253711B (it) 1991-12-17 1991-12-17 Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali

Publications (2)

Publication Number Publication Date
KR930012015A true KR930012015A (ko) 1993-07-20
KR0149519B1 KR0149519B1 (ko) 1998-10-15

Family

ID=11337881

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920012471A KR0149519B1 (ko) 1991-12-17 1992-07-14 질감염 치료용 질의약 조성물과 그 제조 방법

Country Status (13)

Country Link
US (2) US5314904A (ko)
EP (1) EP0547294B1 (ko)
JP (1) JP2834951B2 (ko)
KR (1) KR0149519B1 (ko)
AT (1) ATE130510T1 (ko)
CA (1) CA2073601C (ko)
DE (1) DE69206245T2 (ko)
DK (1) DK0547294T3 (ko)
ES (1) ES2081531T3 (ko)
GR (1) GR3018205T3 (ko)
IT (1) IT1253711B (ko)
MX (1) MX9204132A (ko)
TW (1) TW217385B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100392363B1 (ko) * 2000-12-26 2003-07-22 한국전자통신연구원 형광체 및 그 제조방법

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6462030B1 (en) * 1999-07-19 2002-10-08 New York Blood Center, Inc. Method for inactivating bacteria associated with bacterial vaginosis using cellulose acetate phthalate and/or hydroxypropyl methycellulose phthalate
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
RU2274442C2 (ru) 2000-03-07 2006-04-20 Раш-Презбитериан-Ст. Лук'С Медикал Сентер Композиции и способы улавливания и инактивации патогенных микроорганизмов и сперматозоидов
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6537538B2 (en) 2000-12-18 2003-03-25 Rush-Presbyterian-St. Luke's Medical Center Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
CN1259049C (zh) * 2001-07-06 2006-06-14 苏坎波公司 包含白介素－2抑制剂和抗菌剂的局部给药组合物
WO2004037225A2 (en) 2002-10-25 2004-05-06 Foamix Ltd. Cosmetic and pharmaceutical foam
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
ES2385477T3 (es) * 2002-11-05 2012-07-25 Fadim S.R.L. Liberación continua y controlada de rifaximina
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
BRPI0411429A (pt) * 2003-06-13 2006-07-25 Idh Holding Aps tratamento de sintomas associados com vaginose bacteriana
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
BRPI0414500A (pt) * 2003-09-19 2006-11-07 Drugtech Corp formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
KR101184138B1 (ko) * 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
JP5244318B2 (ja) * 2003-12-31 2013-07-24 シーマ・ラブス、インコーポレイテッド 発泡性経口アヘン薬投薬形態およびアヘン薬の投与方法
US7125963B2 (en) * 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2006244260A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
WO2007054818A2 (en) * 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
EA200870153A1 (ru) * 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
CA2635994A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Drug delivery system for bioadhesion to a vulvovaginal surface
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) * 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX346660B (es) * 2009-10-27 2017-03-28 Lupin Ltd Dispersion solida de rifaximina.
US20130202654A1 (en) 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
MX2012005883A (es) * 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US8445226B2 (en) 2010-02-01 2013-05-21 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
JP6487534B2 (ja) 2014-09-05 2019-03-20 シンビオミックス セラピューティクス、エルエルシー 細菌性膣炎の治療に使用するためのセクニダゾール
WO2016135219A1 (en) * 2015-02-26 2016-09-01 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Topical composition for the treatment of mucosal lesions
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US20190008784A1 (en) * 2017-07-07 2019-01-10 Symbiomix Therapeutics, Llc Novel secnidazole soft gelatin capsule formulations and uses thereof
WO2019073321A1 (en) * 2017-10-10 2019-04-18 Zenvision Pharma Llp EFFERVESCENT COMPOSITIONS COMPRISING RIFAXIMINE
WO2022090490A1 (en) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI812936L (fi) * 1980-09-25 1982-03-26 Ciba Geigy Ag Nya 2-aminoimidazoler foerfaranden foer deras framstaellning dessa foereningar innehaollande farmaceutiska preparat och deras anvaendning
ZA816635B (en) * 1980-09-25 1982-09-29 Ciba Geigy Novel 2-aminoimidazoles
IT1190445B (it) * 1985-11-08 1988-02-16 Fatro Spa Composizioni veterinarie a base di agenti antimicrobici e loro impiego
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
ATE109978T1 (de) * 1989-03-31 1994-09-15 Lepetit Spa Verwendung von purpuromycin zur behandlung von vaginalinfektionen.
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
GB9001019D0 (en) * 1990-01-17 1990-03-14 Euro Celtique Sa Pharmaceutical aerosol

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100392363B1 (ko) * 2000-12-26 2003-07-22 한국전자통신연구원 형광체 및 그 제조방법

Also Published As

Publication number Publication date
CA2073601A1 (en) 1993-06-18
DE69206245T2 (de) 1996-05-02
KR0149519B1 (ko) 1998-10-15
DE69206245D1 (de) 1996-01-04
GR3018205T3 (en) 1996-02-29
TW217385B (ko) 1993-12-11
MX9204132A (es) 1993-08-01
DK0547294T3 (da) 1995-12-18
ATE130510T1 (de) 1995-12-15
ES2081531T3 (es) 1996-03-16
JPH05255085A (ja) 1993-10-05
US6140355A (en) 2000-10-31
ITBO910476A0 (it) 1991-12-17
CA2073601C (en) 1996-07-09
IT1253711B (it) 1995-08-23
US5314904A (en) 1994-05-24
EP0547294A1 (en) 1993-06-23
ITBO910476A1 (it) 1993-06-17
JP2834951B2 (ja) 1998-12-14
EP0547294B1 (en) 1995-11-22

Similar Documents

Publication Publication Date Title
KR930012015A (ko) 질 감염의 치료에 유용한 리팍시민을 함유하는 의약조성물
FI63669C (fi) Foerfarande foer framstaellning av en sprutbar germicidal terapeutiskt anvaendbar skumkomposition
US9050253B2 (en) Oleaginous pharmaceutical and cosmetic foam
ES2391563T3 (es) Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor
RU2156127C2 (ru) Препарат местного применения для иммуносупрессии и лечения аутоиммунных или аллергических заболеваний
US5122519A (en) Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
KR20070050040A (ko) 약제학적으로 우수한 국소용 무수 에어로졸 포움
AU632503B2 (en) Method of treating skin injuries using thromboxane a2 receptor antagonists
US20070036731A1 (en) Topical Delivery with a Carrier Fluid
KR900009057A (ko) 의약용 에어로졸 제제
JPH0466845B2 (ko)
AU668390B2 (en) Supersaturated topical compositions
US4923862A (en) Topical preparation containing ofloxacin
CA2074503C (en) Pharmaceutical formulation containing penciclovir
JP2001511793A (ja) 制汗剤組成物
CA1081124A (en) Thiazole derivatives
JP2865867B2 (ja) ペンシクロビル含有の局所用組成物
AU676200B2 (en) 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions
JPH0366618A (ja) 薬学的配合物
CN110430869A (zh) 直肠泡沫配制物
WO1988006878A1 (en) Pharmaceutical composition containing benzoic acid ester and kit
RU2078564C1 (ru) Липосомный состав для купирования асептического воспаления
JPS61289045A (ja) 外皮投与用組成物

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120601

Year of fee payment: 15

EXPY Expiration of term